ERBB family members including epidermal growth factor receptor (EGFR) also known as HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4 are aberrantly activated in multiple cancers and hence serve as drug targets and biomarkers in modern precision therapy. The therapeutic potential of HER3 has long been underappreciated, due to impaired kinase activity and relatively low expression in tumors. However, HER3 has received attention in recent years as it is a crucial heterodimeric partner for other EGFR family members and has the potential to regulate EGFR/HER2-mediated resistance. Upregulation of HER3 is associated with several malignancies where it fosters tumor progression via interaction with different receptor tyrosine kinases (RTKs). Studies also implicate HER3 contributing significantly to treatment failure, mostly through the activation of PI3K/AKT, MAPK/ERK and JAK/STAT pathways. Moreover, activating mutations in HER3 have highlighted the role of HER3 as a direct therapeutic target. Therapeutic targeting of HER3 includes abrogating its dimerization partners' kinase activity using small molecule inhibitors (lapatinib, erlotinib, gefitinib, afatinib, neratinib) or direct targeting of its extracellular domain. In this review, we focus on HER3-mediated signaling, its role in drug resistance and discuss the latest advances to overcome resistance by targeting HER3 using mono-and bispecific antibodies and small molecule inhibitors.
Introduction
The four members of human epidermal growth receptors (EGFR/HER) family are EGFR/ERBB1/HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4. These are expressed widely in numerous cells such as epithelial, neuronal, tumor and mesenchymal cells. 1,2 ERBB family members are known to regulate several cellular processes including cell division, cell proliferation, differentiation, angiogenesis and tumor progression. 1 All ERBB family members share a common molecular structure consisting of an extracellular domain (ECD), a transmembrane domain, an intracellular domain with tyrosine kinase (TK) activity and a c-terminal tail. The ERBB members generally exist in a tethered confirmation in equilibrium with an open conformation, except for HER2. HER2 has no known highaffinity ligands and has a constitutive active conformation with its dimerization loop open and exposed. 3 EGFR binds to several ligands including EGF, epiregulin, betacellulin, TGF-α. Neuregulins (NRG) also known as Heregulins (HRG) bind to HER3 and HER4. 4, 5 Binding of ligands lead to receptor dimerization, activation of tyrosine kinases and c-terminal tail phosphorylation of tyrosines. This leads to recruitment of adaptor proteins that trigger activation of downstream PI3K/AKT, MAPK and JAK/STAT pathways imparting several biological processes ultimately leading to tumor progression. 2, 5, 6 HER3 possesses impaired kinase activity and preferably heterodimerizes with HER2. HER3 heterodimerizes with RTKs to activate oncogenic signaling via the PI3K/AKT pathway. HER3 and downstream PI3K/AKT signaling is a major cause of treatment failure. 7 NRG-1 and NRG-2 are high affinity ligands for HER3. In the absence of ligands, HER3 sub-domain arm II is locked in a tethered auto-inhibitory configuration, refraining from forming homo-or heterodimers. However, HER3 heterodimerizes with HER2 in ligand-independent manner in HER2-amplified cells. 8 Recent clinical strategies focus on direct targeting of HER3 using monoclonal antibodies (mAbs), which avert ligand-induced activation. This review focuses on the latest advances in our understanding regarding the role of HER3 in tumorigenesis and drug resistance in cancer and also discusses novel strategies for therapeutic targeting of HER3 in cancer treatment.
HER3 structure and role in oncogenesis
HER3, first identified by Kraus et al. is located on the long arm of chromosome 12 (12q13). 9 It is encoded by 23,651 base pairs and translates into 1342 amino acids. HER3 ECD is divided into four sub-domains (I-IV), which includes two cysteine-rich regions (II and IV) and two flanking domains (I and III) that determine specificity for ligand binding. Cys-721, His-740 and Asn-815 have non-conservative substitutions in HER3 which diminishes the catalytic activity of TK domain of HER3 indicating that HER3 utilizes alternative pathway for its activation. 10 Enhanced expression of HER3 is associated with malignancies of several cancers including ovarian, breast, prostate, gastric, bladder, lung, melanoma, colorectal and squamous cell carcinoma. [11] [12] [13] [14] [15] [16] [17] [18] [19] HER3 is the preferred heterodimeric partner for EGFR in melanoma and pancreatic carcinoma. 17, 20 Co-expression of HER2 and HER3 is common in breast cancer and breast cancer derived cell lines. 21 HER3 plays a critical role in HER2-mediated tumorigenesis. Tumors occurring in mice overexpressing the neu transgene exhibit increased expression and activation of HER3. 22 Inhibition of HER2 using tyrosine kinase inhibitors (TKIs) suppresses HER3-mediated downstream activation of PI3K signaling in HER2-overexpressing cells. 23 HER3 is crucial for HER2 for maintaining cell viability in HER2-expressing breast cancer cells. 24 Attenuation of HER3 abrogates HER2-mediated transformation of mammary epithelium in transgenic mice model. 25 HER2 cannot directly bind and activate p85, the regulatory subunit of PI3K. However, HER3 contains six p85-binding motifs, which gets activated by HER2 via heterodimerization, and triggers PI3K signaling. Also, inhibition of HER2 TK activity results in upregulation of HER3 transcription and phosphorylation. This compensatory activation of HER3 partially maintains PI3K/AKT signaling. 26, 27 These data suggest that HER2-dependent breast cancers rely on HER3 to drive oncogenic signaling. HER3 is emerging as a crucial biomarker in luminal breast cancers. HER3 mRNA is expressed significantly in estrogen receptor positive (ER+) or luminal tumors, consistent with the observation that HER3 is essential for cell survival in the luminal but not the basal normal mammary epithelium. [28] [29] [30] HER3 neutralizing antibodies in combination with anti-estrogen treatment result in decreased tumor cell growth and delayed resistance. 29, 31, 32 HER3 mutations are more frequently identified in the ECD with fewer mutations in the intracellular KD. 33 The oncogenic potential of most HER3 mutants depends on HER2 for its transforming potential. 34, 35 HER3 mutations are common in gastric (12%) and colon cancer (11%). HER3 mutants are reported to transform breast epithelial and colonic cells in a ligand-independent manner. 34 Figure 1 illustrates HER2/HER3-mediated signaling pathways.
The role of HER3 in resistance to hormonal therapy
Recently, HER3 activation has been linked to resistance to the ER antagonist, tamoxifen. Enhanced HER3 expression helps breast cancer cells to bypass responsiveness to normal endocrine therapies. 36, 37 Clinical studies also indicate that breast cancer patients with co-expression of HER2 and HER3 are more likely to relapse on tamoxifen. 38 Liu et al. demonstrates that attenuation of HER3 using siRNA abrogates HER2-mediated tamoxifen resistance in breast cancer cells. Inhibition of HER3 significantly increases tamoxifen-induced growth inhibition of MCF7 cells and HER2 overexpressing MCF7 cells via enhanced apoptosis however, does not alter expression or activation of ERα. 39 Increased sensitivity of MCF-7 cells to tamoxifen upon HER3 downregulation could be due to decreased p-AKT levels as AKT signaling is associated with tamoxifen resistance in breast cancer cells. 40, 41 Elevated expression of HER3 in Castration-Resistant Prostate Cancer (CRPC) leads to activation of PI3K/AKT signaling and androgen receptor (AR) stabilization. 42 ER+ breast cancer cells when treated with the ER downregulator, fulvestrant induce protein expression and activity of HER3. 43 Another study demonstrates that fulvestrant resistant MCF-7 cells depend on increased HER3 and NRG-2 expression to maintain their growth and survival. 44 Therefore, HER3 might serve as a crucial biomarker in estrogen withdrawal therapy in luminal breast cancers and in regulating ER-mediated pathways. 
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The role of HER3 in resistance to targeted therapy
The two approaches that are frequently used in ERBB targeted therapy are: i) using monoclonal antibodies or antibody-drug conjugates (pertuzumab, trastuzumab [Herceptin] or T-DM1 to target HER2 and cetuximab, panitumab to target EGFR); or ii) tyrosine kinase inhibitors (erlotinib and getinib to target EGFR, lapatinib and neratinib to target HER2). In spite of EGFR and HER2 targeted therapies having shown tremendous success in treating a wide variety of cancers, most tumors are susceptible to resistance to these therapies within months of treatment.
Several studies indicate that activation of HER3 signaling is one major cause of treatment failure to EGFR or anti-estrogenbased therapies. 45, 46 Yonesaka et al. demonstrates that a subset of colorectal cancer patients acquire resistance to cetuximab-based therapy because of high levels of circulating NRG that induces activation of HER3. 47 Dual targeting of EGFR and HER3 is capable of overcoming acquired resistance to cetuximab and erlotinib further highlighting the role of HER3 in EGFR-targeted therapy. 48 MET amplification in lung cancer leads to gefitinib resistance via activation of HER3 signaling. 49 Additionally, transcriptional upregulation of HER3 is reported to be involved in resistance to MEK/RAF inhibitors in melanoma and thyroid carcinomas. 50, 51 The BRAF inhibitor vemurafenib (PLX4032) upregulates HER3 expression through FOXD3 transcription factor leading to resistance in BRAF-mutant melanoma. 50 Vemurafenib increases HER3 signaling via induction of HER3 transcription through decreased promoter occupancy by the transcriptional repressors CtBP1/2, and through autocrine secretion of NRG-1. 51 Targeting HER2 with lapatinib overcomes the resistant phenotype indicating the HER3-induced resistance is dependent on HER2 expression in both melanoma and thyroid carcinoma. 50, 51 Genetic and functional studies on trastuzumab indicate that activation of PI3K/AKT and SRC signaling are major determinants of trastuzumab-induced resistance. 52, 53 Studies also indicate that HER3 and IGF-1R-dependent signaling mechanisms contribute to trastuzumab-mediated resistance in several cancers. [53] [54] [55] Huang et al. demonstrates that the heterotrimeric complex between HER3/HER2/IGF-1R is a key player in trastuzumab-mediated resistance in breast cancer. The authors also show that specific knockdown of HER3 decreases phosphorylation of AKT, SRC and increases trastuzumab-induced growth suppressing effects in resistant breast cancer cells. 56 Resistance to lapatinib in HER2-positive breast cancer cells is due in part via upregulation of HER3. HER3 mRNA and protein levels are upregulated upon inhibition of the HER2 kinase activity using lapatinib and downstream PI3 kinase using XL147, suggesting that HER3 mediates drug resistance in HER2-enriched breast cancer. 26, 57 Research indicates that HER3 signaling contributes to chemotherapy resistance in ovarian cancer. Doxorubicin upregulates NRG to trigger HER3/PI3K pathways in these tumors. 58 Also, activation of HER3 signaling plays a vital role in progression of mCRPC into docetaxel-based chemotherapy. 42 Knuefermann et al. illustrates that increased resistance to several chemotherapeutic agents like doxorubicin, 5-flurouracil, paclitaxel, camptothecin and etoposide is associated with co-expression of HER2/HER3 and induced activation of PI3K/AKT signaling. 59 Enhanced expression of HER3 confers paclitaxel resistance in HER2+ breast cancer cells via AKTmediated upregulation of survivin. 60 
Anti-HER3 targeted therapies in clinic
Anti-HER3 therapies are based on targeting HER3 in one of the following mechanisms: i) locking HER3 in the tethered confirmation; ii) trapping its ligand, NRG; iii) blocking ligand binding sites; iv) triggering the internalization of the HER3 receptor; v) abrogating dimerization with other EGFR family members; or vi) employing immune cells to kill cancer cells expressing endogenous HER3. The targeted therapies against HER3 include use of mono-/bi-specific antibodies, [61] [62] [63] anti-HER3 vaccines, 64 bi-specific ligand traps for HER3, 65, 66 HER3-locked nucleic acid based RNA inhibitors, 67 small molecule inhibitors against HER3-pseudokinase activity. 68 Tables 1 and 2 [86] Preclinical --HNSCC (in combination with cetuximab) [87] Preclinical --NSCLC (in combination with docetaxel) [88] Phase II Merrimack -NRG+, locally advanced or metastatic NSCLC patients (in combination with docetaxel or pemetrexed) [89] Phase II Merrimack Advanced NSCLC (in combination with erlotinib) [90] Phase Phase II Merus NV and with endocrine therapy in ER+ and low HER2 breast cancer [146] HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung carcinoma; MBC, metastatic breast cancer; TNBC, triple negative breast cancer; ESCC, esophageal-squamous cell carcinoma; EGFR, pithelial growth factor receptor; IGFR, insulin like growth factor receptor; HR, hormone receptor; ER, estrogen receptor; 5'-FU, 5'-fluororuracil; NRG, neuregulin; PR, progesterone receptor; RAIR, radioiodine-refractory; GE, gastroesophageal.
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HER3-targeted therapies. Table 3 briefly describes the clinical trials, outcomes and adverse effects.
Monoclonal antibodies against HER3
Patritumab (U3-1287/A888) is a mAb directed against HER3 ECD. It induces HER3 internalization by preventing ligand binding, dimerization and suppresses tumor growth in HER3 expressing in vivo mice models. 69 It has also been investigated in several clinical and preclinical cancer models including colorectal and lung carcinoma. [69] [70] [71] [72] Cancer cells treated with patritumab show reduced cellular migration, proliferation, and anchorage-independent growth. In addition, EGFR-and HER3-expressing xenografts treated with patritumab and anti-EGFR antibody, cetuximab exhibit significantly reduced tumor growth compared to single antibody. 69 Patritumab inhibits erlotinib-induced resistance in NSCLC and abrogates HER3-AKT signaling cascade. 72 A combination phase I clinical trial with erlotinib in Japanese patients with advanced stage NSCLC shows an overall response rate of 4.2% and disease control rate of 62.5%. 71 A phase III randomized, double-blind, multi-center, two-part study of patritumab in combination with erlotinib in EGFR wild-type patients with locally advanced or metastatic NSCLC patients who have progressed on at least one prior systemic therapy is terminated. 73 The current phase II trial including patritumab in combination with cetuximab, cisplatin and carboplatin is completed in patients with HNSCC. 74 A phase Ib/II clinical trial evaluating the efficacy of patritumab, trastuzumab plus paclitaxel in metastatic breast cancer is terminated due to variation in patients' standard of care. 75 U3-1402 is a modified antibody consisting of patritumab covalently conjugated with MAAA-1162a, a drug linker with a drug component MAAA1181a. U3-1402 is in ongoing phase I trial in patients with NSCLC. 76 Seribantumab (MM-121) is a humanized mAb targeting the ECD of HER3 that prevents binding of NRG, blocks heterodimerization and induces HER3 internalization and degradation. 61 Seribantumab is investigated in phase I and II clinical trials in combination with anti-cancer drugs or chemotherapy that covers a broad spectrum of cancer patients. [77] [78] [79] [80] [81] [82] [83] The clinical and preclinical studies in ovarian, breast, HNSCC and NSCLC cancers identified NRG as patient response biomarker for seribantumab. [84] [85] [86] [87] [88] A phase II study evaluating MM-121 in combination with docetaxel and pemetrexed in NSCLC patients with high NRG expression is still ongoing. 89 Another phase I/II study of MM-121 in combination with erlotinib is completed in patients with NSCLC. 90 There is an ongoing phase II trial where NRG+, HER negative (-) postmenopausal breast cancer patients are subjected to treatment with seribantumab and fulvestrant. 91 A randomized phase II trial of exemestane in combination with seribantumab is completed in postmenopausal women with locally advanced or metastatic ER+ and/or progesterone receptor positive (PR+) HER2-breast cancer. 92, 93 Another non-randomized, open-label study of seribantumab plus MM-151, MM-141, or trametinib in patients with advanced NRG+ NSCLC, HNSCC, colorectal cancers initiated by Merrimack is terminated. 94 A phase I study exploring the role of seribantumab indicates that it can be combined at its recommended single agent dose with standard doses of gemcitabine, pemetrexed, cabazitaxel and adapted doses of carboplatin for treatment of patients with advanced solid tumors. 95 A study exploring the role of seribantumab in combination with PI3K inhibitor, SAR245408 is completed in patients with solid tumors. 96 Lumretuzumab (RG7116, RO-5479599) is a humanized glycol-engineered mAb, which suppresses the activation of HER3 signaling by blocking HER3 ECD and preventing NRG binding. It engages immune cells to cause antibody-dependent cell-mediated cytotoxicity (ADCC). 97, 98 Currently, there are three clinical trials reported using RG7116. A phase I trial testing the combination of RG7116 with paclitaxel and pertuzumab targeting HER3+ breast cancer has been completed. 99, 100 A phase I study with RG7116 illustrates an overall disease control rate of 21% in patients with advanced HER3-positive solid tumors. 101 A phase Ib/II trial of RG7116 in combination with carboplatin and paclitaxel although initiated in patients with NSCLC is terminated. 102 A phase Ib study of RG7116 plus cetuximab/erlotinib identified NRG as potential biomarker in patients with solid tumors. 103 Elgemtumab (LJM716), a human anti-HER3 IgG1 binds to HER3 ECD, locks it in tethered conformation and prevents activation of HER3 and inhibits tumor growth in vivo. 104, 105 Novartis initiated a phase Ib/II clinical trial of LJM716 in combination with cetuximab in platinum-pretreated recurrent/metastatic patients with HNSCC. However, the study is withdrawn. 106 There is ongoing phase I clinical study of LJM16 in combination with trastuzumab, BYL719 in HER2+ breast cancer patients. 107 A phase I study evaluating the combination of LJM16 with trastuzumab in patients with HER2 expressing metastatic breast or gastric cancer is completed. 108 LJM716 has also been tested for the safety and efficacy in phase I trial for esophageal squamous cell carcinoma. 109 [157] Preclinical --EV20-Sap (melanoma) [158] Preclinical -HER3 nanobiologics HER3 -HerPNK 10 (Her-PBK) recombinant polypeptide Preclinical -in breast cancer [159] HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung carcinoma; NRG, neuregulin. [78, 81] with cetuximab: 400 mg/m 2 (loading dose) followed by 200 or 250 mg/m 2 (maintenance dose) weekly by IV and irinotecan: 180 mg/m 2 , once every 2 weeks by IV route. Preoperative TNBC and HR+, Phase II The drug alone or in combination exhibited a Diarrhea, rash, febrile neutropenia, fatigue, anemia, HER2-breast cancer favorable safety profile. Benefit from hypokalemia, pulmonary embolism, hyperglycemia. (in combination with paclitaxel) MM-121 treatment was only observed in the HR+ [79, 82] group and was not observed in the TNBC group. MM-121 at loading dose of 40 mg/kg in the first week by IV route followed by 20 mg/kg for maintenance dose was administered along with standard doses of paclitaxel IV, doxorubicin IV and cyclophosphamide IV, followed by surgery.
Continued on the next page.
[ protein (in combination every 3 weeks via IV infusion with paclitaxel in combination and pertuzumab) [99, 100] with pertuzumab (loading dose: 840 mg, every 3 weeks via IV infusion and maintenance dose: 420 mg, every 3 weeks via IV infusion) and paclitaxel 80 mg/m 2 , weekly via IV infusion.
Diarrhea, fatigue, decreased appetite, infusion Metastatic or advanced Phase I Dose escalation range was from 100 mg to 2000 mg related reactions, constipation, neutropenia, HER3+ solid tumors [101] every 2 weeks, via IV infusion. Lumretuzumab thrombocytopenia. was well tolerated up to dose of 2,000 mg. The linear PK characteristics indicated target-mediated drug deposition saturation. PD effects were observed in serial tumor biopsies and indicated that the active biological dose of the drug is form 400 mg onwards. The disease control rate was 21%. Advanced/metastatic NSCLC Phase Ib/II The study has been terminated.
-(in combination with carboplatin (terminated) and paclitaxel) [102] Solid tumors (in combination Phase Ib The toxicity profile of lumretuzumab GI related disorders, skin toxicities. with cetuximab or erlotinib) [103] (dose range from 400 mg to 2000 mg) with erlotinib or cetuximab was manageable with modest clinical activity observed across tumor type. The study failed to identify a robust biomarker signal that could serve as response prediction biomarker for lumretuzumab. [108] Trastuzumab (2 mg/kg) was administered once weekly by IV route.
ESCC (in combination with
Phase Ib/II Dose range of LJM716 was from 10 mg/kg BYL719, paclitaxel, docetaxel, to 40 mg/kg, once weekly by IV infusion. irinotecan) [109] BYL719 (200 mg-400 mg) was administered once daily p.o. Paclitaxel, docetaxel and irinotecan were administered along with the combination in phase 2 of the study. -ESCC, HNSCC, Phase I LJM716 was found to be tolerated upto Diarrhea, chills, infusion-related reactions, HER2-overexpressing 40 mg/kg when administered once weekly reduced appetite, GI disorders, hypokalemia. MBC or gastric cancer [110] via IV infusion. This was also the recommended phase 2 dose. It demonstrated preliminary evidence of antitumor activity. Advanced solid tumors [111] Phase I LJM716 was well tolerated in Japanese Diarrhea, stomatitis, paronychia, fatigue, pyrexia, patients with a manageable safety profile.
pneumonia, decreased lymphocyte count, nausea, The recommended dose was established vomiting. at 40 mg/kg, once a week by IV, route to Japanese patients.
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[ [118, 119] range of 2 mg/kg to 20 mg/kg administered skin, hypomagnesemia, headache, dehydration, via IV infusion once every 2 weeks. The recommended phase 2 dose was established as 20 mg/kg IV every 2 weeks. dizziness, dyspnea, anemia, pruritus.
GSK2849330
Advanced HER3+ Phase I Completed, not published. -solid tumors [120, 121] REGN1400 NSCLC, colorectal cancer, Phase I REGN1400 alone or in combination with erlotinib Rash, diarrhea, nausea, hypomagnesemia, increased HNSCC (in combination with or cetuximab was well tolerated at the dose range AST, dry skin, fatigue, stomatitis, pneumonia, erlotinib or cetuximab) [122] of 2 mg/kg to 20 mg/kg via IV route, pyrexia, sepsis once every 2 weeks. The recommended phase 2 dose of 20 mg/kg by IV route, once every 2 weeks. The combination therapy failed to potentiate any anti-EGFR related adverse effects. Duligotuzumab Locally advanced or metastatic Phase I MEHD7945A was well tolerated as a single agent Diarrhea, nausea, chills, headache, fever. (RG7597, epithelial tumors [130] with a PD and antitumor activity in HNSCC MEHD7945A) patients in dose escalating studies with dose range from 1mg/kg to 30 mg/kg administered by IV every 2 weeks. The recommended phase 2 study flat dose was established at 1100 mg twice daily in HNSCC and colorectal cancer patients. Locally advanced or metastatic Phase Ib The study did not proceed to expansion stage Hypokalemia, mucosal inflammation, asthenia, cancers with mutated KRAS and was closed for enrollment due to dose dermatitis acneiform. (in combination with cobimetinib) limited tolerability and efficacy of the combination. [131, 133] KRAS wild-type metastatic colorectal Phase II Duligotuzumab did appear to improve Diarrhea, skin rashes. cancer (in combination with outcomes in the patients. FOLFIRI-5-fluororuracil, follinic It dialed to provide progression free survival acid and irinotecan vs (PFS) or overall survival (OS) benefit vs cetuximab. cetuximab) [132, 134] Recurrent or metastatic HNSCC Phase II Duligotuzumab was 1100 mg, once every 2 weeks Infections, GI related disorders. (during or following platinum by IV route. Cetuximab (loading dose: 400 mg/m 2 therapy vs cetuximab) [135, 136] and maintenance dose: 250 mg/m 2 ) was administered once weekly by IV route. Dual inhibition of HER3 and EGFR by duligotuzumab demonstrated a comparable activity (in randomized and biomarker positive patients) and not superior activity as compared to single agent cetuximab in HNSCC. HPV-negative HNSCC patients but not HPV-positive HNSCC patients may possibly respond to cetuximab or duligotuzumab. Recurrent or metastatic HNSCC Phase Ib/II The trial studied the feasibility of combination Neutropenia, hypokalemia, dehydration, anemia, (in combination with cisplatin/5'-FU of duligotuzumab at 1650 mg diarrhea, febrile neutropenia, leukopenia, or carboplatin/paclitaxel) [137] (recommended phase 2 dose), thrombocytopenia, hypomagnesemia. by IV route, every 3 weeks with combination of cisplatin/5'-FU or carboplatin/paclitaxel. The combinations demonstrated an antitumor effect. But the study was limited by an increased frequency and severity of adverse events.
[Oncology Reviews 2018 [139] escalation cohorts weekly via IV route. myocarditis, peural effusion. Advanced HER2 amplified, Phase I MM-111 was combined with Herceptin for dose Anemia, GI related disordera, UTI, decreased NRG+ breast cancer escalation cohorts and administered weekly or appetite, insomnia, anxiety, skin toxicities, (in combination with bi weekly via IV route. pericardial effusion, pleural effusion, deep vein herceptin) [140] thrombosis. Advanced HER2+
Phase I MM-111 was dosed weekly at 10 mg/kg Anemia, acute renal failure, chest pain, decreased solid tumors (along with different and where possible, the dose was escalated appetite, diarrhea, febrile neutropenia, combination treatment till 20 mg/kg. In the arm where the patients hyperuricemia, hypokalemia, hyponatremia, of capecitabine/cisplatin/ were treated with MM-111, docetaxel and trastuzumab, mucosal inflammation, nausea, trastuzumab/lapatinib/ the agent was dosed from 30 mg/kg and escalated thrombocypopenia, vomiting. paclitaxel or docetaxel) [141] to 40 mg/kg via IV infusion, once every 3 weeks. A fixed dose of istiratumab-2.8 grams, and gemcitabine) [144] twice every week by IV route was selected for the study.
MCLA-128
Malignant solid tumors [145] Phase I/II MCLA-128 was well tolerated and exhibited Diarrhea, nausea, vomiting, fatigue, maculopapular a favorable safety profile in patients rash, oral mucositis, G2 neutropenia at doses upto 900 mg, every 3 weeks via IV infusion. Based on the PK profile and the anti-tumor activity, the recommended phase 2 dose of MCLA-128 was set at 750 mg, every 3 weeks via IV infusion. once every 2 weeks via IV route. dizziness, dyspnea, dry skin, pruritus. The recommended phase 2 dose was calculated to be 20 mg/kg, every 2 weeks by IV route.
HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung carcinoma; MBC, metastatic breast cancer; TNBC, triple negative breast cancer; ESCC, esophageal-squamous cell carcinoma; HR, hormone receptor; ER, estrogen receptor; 5'-FU, 5'-fluororuracil; NRG, neuregulin; PR, progesterone receptor; RAIR, radioiodine-refractory; GE, gastroesophageal; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DLT, dose limiting toxicity; PK, pharmacokinetic; PD, pharmacodynamic; IV, intravenous; p.o., per oral; GI, gastrointestinal; UTI, urinary tract infection.
that LJM716 is well tolerated with a recommended daily intravenous dose of 40 mg/kg. 111 KTN3379, an anti-HER3 mAb inhibits HER3 activity in ligand-dependent and independent manner. 112 A phase I study evaluating the efficacy of KTN3379 either alone or in combination with various drugs (cetuximab, erlotinib, vemurafinib, trastuzumab) has been completed in advanced solid tumors. 113, 114 A pilot phase I study initiated by Celldex Therapeutics testing whether vemurafenib with the addition of KTN3379 can restore iodine incorporation in BRAF mutant melanoma and radioiodine-refractory (RAIR) thyroid cancer patients is also completed. 115 A study of KTN3379 in surgically resectable HNSCC patients is completed which evaluated the effect of KTN3379 on HER3 activation and other biomarkers in tumor tissues. 116 AV-203 is an anti-HER3 IgG1 which binds to the HER3 receptor and prevents NRG binding. AV-203 shows preclinical activity against patient-derived tumor explant models and suppresses HER3 activation and downstream signaling. 117 Phase I clinical trial in advanced solid tumors is now completed. 118, 119 GSK2849330 is a HER3 targeting antibody which has completed a phase I clinical trial in HER3+ patients with solid tumors. 120,121 REGN1400, another HER3 mAb investigated alone or in combination with erlotinib or cetuximab in several metastatic cancers. 122 REGN1400 significantly suppresses HER3 downstream signaling and in combination with EGFR mAb, inhibits the growth of xenograft tumors derived from HNSCC and colorectal cancer. 123 MP-RM-1 is a murine mAb against HER3 which induces HER3 internalization and degradation and attenuates liganddependent and independent HER3 signaling in several cancers including breast, melanoma, prostate and gastric cancer. 124 EV20, a humanized version of MP-RM-1 (Mediapharma S.r.l) inhibits HER2-HER3 heterodimerization, downregulates HER3 and also internalizes it into the tumor. 125, 126 It is also shown to reverse the resistance to vemurafenib in BRAF-V600E mutant colon cancer stem cell. 127 Duligotuzumab (RG7597, MEHD7945A) is a phage derived humanized bi-specific antibody targeting both HER3 and EGFR. It prevents ligand binding and favors HER3 internalization and ADCC. 128 It has shown significant efficacy in several in vivo models. 48, 129 This antibody is explored in phase I & II clinical trials in various metastatic cancers. [130] [131] [132] [133] [134] A phase II randomized trial compares the safety and efficacy of MEHD7945A versus cetuximab in metastatic HNSCC patients who have progressed during or following platinum-based chemotherapy. 135, 136 A phase Ib study of MEHD7945A plus cisplatin/5-fluorouracil or carboplatin/paclitaxel demonstrates an encouraging clinical activity in patients with recurrent/metastatic HNSCC. 137 A phase Ib, open-label, dose-escalation study exploring the safety, tolerability, and pharmacokinetics of MEHD7945A with cobimetinib in patients with locally advanced or metastatic solid tumors with mutant KRAS is completed. 131, 133 MM-111 is a bi-specific antibody that forms a trimeric complex with HER2 and HER3. MM-111 is shown to be more efficient in xenograft tumors derived from HER2+ cancer cell lines where it exhibits significant anti-tumor activity in combination with trastuzumab or lapatinib. 63 However, the phase II clinical trial involving combination of MM-111 and trastuzumab is terminated in gastric cancer. 138 A phase I clinical trial involving MM-111 in combination with trastuzumab has been completed in HER2 amplified and NRG+ breast cancer. 139 The other clinical trial sponsored by Merrimack is in advanced HER2 amplified and NRG+ solid tumors. 140 A multi-arm dose escalating study of MM-111 plus HER2 targeting regimens including capecitabine, cisplatin, trastuzumab, lapatinib, paclitaxel, docetaxel evaluating the safety, pharmacokinetics (PK), and anti-tumor activity of MM-111 in patients with advanced HER2+ solid tumors has been completed. 141 Another bi-specific antibody, MM-141 (istiratumab) has been developed against HER3 and IGFR by Merrimack. 62 MM-141 inhibits binding of NRG to HER3 and IGF-1/2 to IGFR and abrogates PI3K/AKT signaling and also increases efficacy of gemcitabine in preclinical models. 62 MM-141 has been investigated in a phase I clinical trial either alone or in combination with gemcitabine, everolimus or paclitaxel in advanced solid tumors. 142, 143 A phase II study exploring the efficacy of MM-141 in combination with nab-paclitaxel and gemcitabine is still going on in metastatic pancreatic cancer. 144 MCLA-128 is a bispecific antibody targeting HER2 and HER3 in phase I/II trial in patients with solid tumors. 145 A phase II study is initiated to evaluate the safety and efficacy of MCLA-123 in combination with trastuzumab/chemotherapy in HER2+ and with endocrine therapy in ER+ metastatic breast cancer. 146 
Other anti-HER3 targeted therapies Antisense oligonucleotide
RNAi therapy is an emerging anti-HER3 strategy to treat cancers, which are not sensitive to anti-HER3 antibodies. EZN-3920 is a nucleic acid based HER3 anti-sense oligonucleotide, which inhibits HER3 expression and HER3-mediated downstream signaling and in vivo tumor growth. 67 It also demonstrates significant anti-proliferative effects in trastuzumab-and gefitinib-resistant cell lines. EZN-3920 in combination with lapatinib or gefitinib increases the anti-tumor activity compared to single agent. 67 However, lack of efficient delivery systems of RNA antagonists curtails efficient application in the clinic. 147
HER3-peptide vaccine
Peptide vaccines targeting HER3 could induce HER3 neutralizing antibodies in cancer. HER3 epitopes encompassing residues 99-122, 140-162, 237-269 and 461-479 of HER3 are explored as active immune therapy against breast and pancreatic cancer. These mimics show enhanced anti-tumor effects in breast and pancreatic cancer cells. 64 
Ligand traps
A HER ligand binding molecule which could sequester different ligands for multiple receptors is a recent approach to treat cancers where there is activation of alternate compensatory loops due to other EGFR family members. RB200 is a bi-specific ligand trap which binds to multiple ligands including HER3 ligand NRG, EGFR ligands including TGFα, heparin binding EGF. RB200 suppresses EGF-and NRG1-β1-induced phosphorylation of HER family RTKs and cancer cell proliferation as a single agent and in synergy with tyrosine kinase inhibitors, lysophosphatidic acid-induced cell proliferation, and tumor growth in xenograft mice models. 65 However, this strategy has not been applied in the clinic.
Pan-HER approach
Pan-HER approach includes six antibodies for synergistic targeting of EGFR, HER2 and HER3, with the goal of preventing compensatory activation of EGF receptors where only one receptor is inhibited. This mixture is tested against 100 different cancer cell lines where it significantly attenuates cancer cell proliferation and outperforms the activity of reference antibodies (cetuximab, transtuzumab and MM-121). 66, 148 Sym013 developed by Symphogen is a mixture of six humanized mAbs targeting EGFR, HER2 and HER3, which demonstrates better anti-tumor activity in in vivo models. 149 Currently, an open-label, multicenter, phase Ia/IIa trial investigating the safety, tolerability and anti-tumor activity of multiple doses of Sym013 is initiated in patients with advanced epithelial malignancies. 150
HER3 ligands as predictive biomarkers and anti-HER3 target
Several preclinical and clinical studies indicate that NRG is a predictive biomarker for HER3-targeted therapies. NRG expression correlates with in vivo tumor regression and has been validated in the clinic. 151, 152 In a phase I clinical trial, NRG-positive patients with metastatic or advanced tumors show a partial response to HER3-specific mAb, AV-203. 153 Inhibition of HER3 using AV-203 correlates with NRG expression in preclinical studies. 117 Elevated NRG expression corroborates with HER3 activation in head and neck squamous cell carcinomas. 154 However, NRG as a potential biomarker becomes questionable in tumors with HER3 mutations or downstream molecular alterations. Xenograft tumor models with a PTEN mutation show resistance to AV-203 even with elevated NRG expression. 117 In HER2-amplified breast cancer model, HER3 exhibits constitutive activation independent of NRG. 155 
Inhibitor targeting pseudo kinase activity of HER3
A selective small molecule TX1-85-1 interacts with cys721 in the ATP-binding pocket of HER3. TX-121-1, a derivate of TXI-85-1 causes partial degradation of HER3, interferes with dimerization with c-Met and HER2, perturbs HER3-mediated signaling. More studies are essential to validate the role of these inhibitors in HER3-targeted therapeutics. 68
HER3 as target for antibody-drug conjugates
Antibody-drug conjugates (ADCs) are emerging as an attractive strategy to improve the antibody based therapy for treatment of different cancers. HER3-ADCs shows promising anti-tumor efficacy in a wide range of human cancer. 156 Capone et al. coupled the humanized anti-HER3 mAb, EV20 to the cytotoxic drug monomethyl auristatin F (MMAF) to generate a novel antibodydrug conjugate (EV20-MMAF). This antibody demonstrates target-dependent cell killing activity in a panel of human melanoma cell lines with HER3 expression independent of BRAF status. A single administration of EV20-MMAF causes long lasting tumor growth inhibition and is superior to vemurafenib in abrogating kidney, liver and lung melanoma metastases. 157 EV20-Sap is another HER3-ADC obtained by coupling EV20 to the plant toxin Saporin (Sap). This complex causes target-dependent cytotoxic activity that correlates with internalization and expression of HER3 on cancer cells. EV20-Sap treatment results in significant reduction of pulmonary metastasis in murine melanoma model. 158
HER3 nanobiologic therapeutic approach
Sim et al. demonstrates HER3-targeted nanobiologics as a novel approach effective against resistant tumors expressing HER3. The author synthesized a recombinant polypeptide, HerPBK10 (HPK) having a minimal receptor binding domain from NRG-1. This biocarrier combines several functions within a single fusion protein for mediating target cell penetration and non-covalent self-assembly with therapeutic cargo, forming HER3 homing nanobiologics. These nanobiologics show significant affinity and are effective against tumors showing resistance to inhibitors against HER3 receptor. It is shown that the efficacy of HPKnanobiologics is dependent on HER3 levels of resistant cells as well as naïve cells. 159 
Conclusions
Drug resistance is a major reason of treatment failure that limits the efficacy of several targeted therapies including mono-/bispecific antibodies and small molecule inhibitors against EGFR family members. Targeting other EGFR family members using TKIs leads to feedback upregulation of HER3 encouraging the direct targeting of HER3 as a better option in the clinic. Many HER3 mAbs have been designed and demonstrated significant preclinical efficacy, however, a HER3 targeted treatment has not yet received approval based on clinical trials. Studies indicate that HER3 plays a vital role in drug resistance and overall HER signaling. Encouraging clinical studies suggest that concomitant suppression of HER3 along with other RTKs including EGFR family members may be helpful in attaining greater clinical benefits.
